On June 19, 2012, SACEMA’s Brian Williams, also Senior Technical Adviser to Test & Treat to End AIDS, held a briefing in Washington DC in which he explained to US senators, members of congress, and staff how this strategy has the potential to stop the spread of HIV/AIDS and, over time, to save billions of Read More
The role of treatment as prevention / the test and treat strategy to reduce the HIV incidence continues to be a hot topic
We need to move from theory to practice and fund, implement and evaluate the test-and-treat strategy.
In the first edition of the SACEMA Quarterly (March 2009) Brian Williams provided a discussion on the various arguments for and against the in a Lancet article suggested approach of ‘treatment as prevention’ of HIV (early treatment of HIV infected individuals will prevent transmission of the virus) (1). As this ‘test-and-treat’ strategy continues to be Read More
In this last issue of the SACEMA Quarterly in 2010 we present three main articles on a variety of issues: An update on the evidence for the efficacy of microbicides, including the cost-effectiveness of this intervention; The emerging issue of abuse and neglect experienced by AIDS orphans (and other vulnerable children) and their perceived social support; The enormous rise in the prevalence of drug abuse and the increase in the need for treatment. We also have short items providing information on the early work on tsetse by Glyn Vale; An update on the ‘treatment as prevention’ issue; And an item on the issue of the importance of concurrency in the high incidence rate of HIV in Africa. We hope you will all enjoy reading this issue. Next year we will continue publishing the SACEMA Quarterly magazine after giving it a slight makeover.
At the 3rd Annual Congress of ISPOR South Africa, Wim Delva – senior researcher at SACEMA – gave a presentation on age-targeted early HIV treatment initiation. As reported earlier in the SACEMA Quarterly, universal, immediate antiretroviral treatment (ART) has the potential to reduce HIV incidence dramatically (1). However, this may not be feasible nor affordable Read More
The central theme of this SACEMA Quarterly is the HIV/TB co-epidemic. From 1-4 June 2010 the 2nd TB conference was held in Durban, in which most of the presentations discussed TB in relation to HIV. A SACEMA affiliate presented a study concluding that intensified HIV testing and early initiation of antiretroviral therapy (ART) for women and men aged 25-40 would optimise the cost-effectiveness of applying the test-and-treat strategy in South Africa, as this would have the largest impact on TB as well. One of the main articles in this Quarterly discusses whether ART will help, and to what extend, in lowering TB incidence. Other articles focus on meaningful statistical modelling in public health, and the Zibambele programme (job creation and poverty alleviation) and it’s role in the battle against HIV/AIDS and TB. Finally, the new director of SACEMA is announced: Dr. Alex Welte.
In November 2009 the Flemish Research Fund and the Flemish Interuniversity Council approved two proposals concerning “Data-driven modelling of the impact of wide-scale, early HIV treatment on the incidence of HIV in South Africa”. Both projects will be launched in 2010 and involve research and capacity building components as well as efforts to intensify the Read More
In November two meetings took place in Geneva on the decision how, if at all, antiretroviral therapy could be used as an offensive weapon against the HIV pandemic – rather than simply in its current defensive role of keeping alive people who have generally already reached late stages of infection. This article reports on the discussions and most important outcomes of these meetings.
The Lancet recently reported that universal HIV testing and immediate antiretroviral therapy (ART) for everyone diagnosed with HIV in countries such as South Africa could reduce new infections by 95% within ten years. This article describes the benefits and objections (costs, human resources, side effects, drug resistance) to the idea of starting all HIV positives on ART in South Africa, including the way forward.